Page 58 - GUÍA CLÍNICA HPN 2023
P. 58
Actualización 2023
58
25. Lee JW, Sicre de Fontbrune F, Lee Lee LW, et al. Rav-
ulizumab (ALXN1210) vs eculizumab in adult patients
with PNH naive to complement inhibitors: the 301
study. Blood. 2019;133(6):530-539. PMID: 30510080.
26. Kulasekararaj AG, Hill A, Langemeijer S, et al. One-year
outcomes from a phase 3 randomized trial of ravuli-
zumab in adults with paroxysmal nocturnal hemoglo-
binuria who received prior eculizumab. Eur J Haematol.
2021;106(3):389-397. PMID: 33301613.
27. Girmenia C, Barcellini W, Bianchi P, et al. Scientific
committee of the Associazione Italiana Emoglobinuria
Parossistica Notturna (AIEPN). Management of infec-
tion in PNH patients treated with eculizumab or other
complement inhibitors: Unmet clinical needs. Blood
Rev. 2023;58:101013. PMID: 36117056.
28. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus
Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med. 2021;384(11):1028-1037. PMID: 33730455.
29. Peffault de Latour R, Szer J, Weitz I, et al. Pegceta-
coplan versus eculizumab in patients with paroxys-
mal nocturnal haemoglobinuria (PEGASUS): 48-week
follow-up of a randomised, open-label, phase 3, ac-
tive-comparator, controlled trial. Lancet Haematol.
2022;9(9):e648-e659. PMID: 36055332.
30. Kulasekararaj AG, Lazana I. Paroxysmal nocturnal he-
moglobinuria: Where are we going. Am J Hematol.
2023;98 Suppl 4:S33-S43. PMID: 36794458.
31. Peffault de Latour R, Schrezenmeier H, Bacigalupo
A, et al. Allogeneic stem cell transplantation in par-
oxysmal nocturnal hemoglobinuria. Haematologica.
2012;97(11):1666-1673. PMID: 22689687.
32. Nakamura Y, Takenaka K, YamazaKi H, et al. Outcome of
allogeneic hematopoietic stem cell transplantation in
adult patients with paroxysmal nocturnal hemoglobin-
uria. Int J Hematol. 2021;113(1):122-127. PMID: 32889696.